在耐火性克朗氏病中,静脉注射乌斯特基努马布的强化
Cristina Suárez Ferrer1,2, José Arroyo Argüelles1, Jose Luis Rueda García1,2
1Inflammatory Bowel Disease Unit, Digestive Medicine Service, Hospital Universitario La Paz, 28046 Madrid, Spain.
通过静脉注射乌斯特基努马布 (IV UST) 加剧克罗恩病治疗改善了患者的治疗结果和在失去对皮下维护的反应后的药物水平. 这种方法对治疗耐火性CD患者充满希望.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克罗恩病 (CD) 的管理通常需要调整治疗.
- 静脉注射 (IV) ustekinumab (UST) 强化在患有二次反应丧失的CD患者的疗效尚未得到充分证实.
研究的目的:
- 为了评估经过IV UST强化治疗的CD患者的临床和生化反应.
- 在切换到IV UST治疗后评估血清药物度.
主要方法:
- 对27名CD患者的回顾性分析,这些患者从皮下 (SC) 转换为IV UST (130毫克每4周).
- 临床和生化反应在强化后12周被评估.
- 在基线和12周测量了血清UST水平.
主要成果:
- 切换为IV UST的患者之前对SC维护失去了反应.
- 在IVUST强化后观察到便calprotectin的减少 (1463至751μg/g,p=0.14).
- 在IVUST强化后12周,血清UST水平增加.
结论:
- 强化IV UST治疗可能会导致CD患者的临床和生化改善,而CD患者的反应会出现次要的丧失.
- 输入性UST强化增加了血清药物水平,可能恢复治疗疗效.
更多相关视频
07:45Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
Published on: September 1, 2017
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Ulcerative Colitis in IBD
